- Texts Boost Breast Cancer Screening Numbers
- Promoting Effective Communication About Breast Cancer Overdiagnosis
- Patient Leaflets Don’t Affect Interest in Mammogram Screening
- Genetic Anomalies Linked to Breast Cancer in African American Families
- FDA Approves New Drug for Patients with Advanced Breast Cancer
- Women with Atypical Hyperplasia Have a Higher Risk of Breast Cancer
- Mastectomy Patients Most Satisfied with Breast Reconstruction Using Their Own Tissues
- Follow Up for Breast Cancer Patients
- Helping Breast Cancer Patients Adhere to Hormone Therapy
- Opportunities Identified that Reduce Breast Cancer Screening Patient Burden
Vegetable Compound Inhibits Pathways that Promote Colon Cancer Growth
Luteolin, a molecule isolated from fruits and vegetables, is able to prevent the growth of cancer cells in the lab. The study has shown that the compound interferes with two key signalling pathways that the cancer cells require.
Luteolin is a flavonoid commonly found in fruit and vegetables. This compound has been shown in laboratory conditions to have anti-inflammatory, anti-oxidant and anti-cancer properties but results from epidemiological studies have been less certain. New research published in BioMed Central’s open access journal BMC Gastroenterology shows that luteolin is able to inhibit the activity of cell signaling pathways (IGF and PI3K) important for the growth of cancer in colon cancer cells.
Colon cancer is the second most frequent cause of cancer-related death in the Western World. Colon cancer cells have elevated levels of IGF-II compared to normal colon tissues. It is thought that this is part of the mechanism driving uncontrolled cell division and cancer growth. Researchers from Korea showed that luteolin was able to block the secretion of IGF-II by colon cancer cells and within two hours decreased the amount of receptor (IGF-IR) precursor protein. Luteolin also reduced the amount of active receptor (measured by IGF-I dependent phosphorylation).
Luteolin inhibited the growth stimulatory effect of IGF-I and the team led by Prof Jung Han Yoon Park found that luteolin affected cell signaling pathways which are activated by IGF-I in cancer. Prof Jung Han Yoon Park explained, “Luteolin reduced IGF-I-dependent activation of the cell signaling pathways PI3K, Akt, and ERK1/2 and CDC25c. Blocking these pathways stops cancer cells from dividing and leads to cell death.”
Prof Jung Park continued, “Our study, showing that luteolin interferes with cell signaling in colon cancer cells, is a step forward in understanding how this flavonoid works. A fuller understanding of the in vivo results is essential to determine how it might be developed into an effective chemopreventive agent.”
Reference: BioMed Central